Deep proteomic screening

CREATE broad portfolios of novel degrader targets

Deep Proteomic Screening identifies high-value degrader targets at an unprecedented scale and provides unique insights into a compound’s proteome-wide effects.

By integrating industrial-scale, single-shot data-independent acquisition mass spectrometry (DIA-MS) with automated and scalable processes, we ensure efficient and reproducible analysis of all degrader types, achieving optimal reproducibility, accuracy, and speed.

To maximize statistical power, we utilize software such as DIA-NN combined with a fully automated proprietary biostatistical analysis pipeline. Our data processing protocol includes rigorous quality control for protein identification and quantification, advanced data filtering, proprietary normalization techniques, batch correction, and sensitive differential abundance testing using refined linear models.

This integrated strategy enables swift and automated analysis of large-scale proteomics datasets, ensuring exceptional precision, data completeness, and sensitivity.

Learn More

	COVERAGE Evaluate degrader compounds against more than 11,000 proteins
	TROUGHPUT Screen degrader libraries containing tens of thousands of compounds
	TURNAROUND Assess proteome-wide selectivity, potency, and efficacy in drug optimization cycles
	CONFIDENCE Detect even subtle protein changes and low-abundance proteins with exceptional sensitivity
	SIGNIFICANCE Achieve best-in-class reproducibility and precision through replicate testing